安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Advancing Precision Treatment in Cholangiocarcinoma Using FGFR Inhibitors
Approximately 10% to 15% of CCA harbors FGFR2 aberrations, and approved inhibitors such as pemigatinib, infigratinib, and futibatinib have paved the way for precision medicine in intrahepatic CCA (iCCA), specifically
- FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)
- Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma | New . . .
Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis
- FGFR2 Inhibition in Cholangiocarcinoma - PubMed
The scope of this review is to provide an overview of oncogenic FGFR signaling in iCCA cells and highlight the pathophysiology, diagnostic testing strategies, and therapeutic promises and challenges associated with FGFR2-altered iCCA
- Targeting FGFR inhibition in cholangiocarcinoma - ScienceDirect
Fibroblast growth factor receptor 2 (FGFR2) alterations occur in up 15% of iCCAs Selective FGFR inhibitors show promise to improve outcomes in FGFR-driven CCA Research to further optimise the use of new and emerging FGFR inhibitors is ongoing
- Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma . . .
Fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs) are oncogenic drivers in 10–15% of intrahepatic cholangiocarcinoma (iCCA) FGFR-specific inhibitors provide temporary benefit in FF+ unresectable patients
- FGFR2 testing in cholangiocarcinoma: translating molecular studies into . . .
The following level II and III actionable genetic alterations have available targeted therapies that do not have any indication for CCAs: microsatellite instability (MSI) mismatch repair deficiency (dMMR), BRAF mutations, ERBB2 amplifications or mutations, PIK3CA mutations, BRCA1 and BRCA2 mutations, MET amplifications
- Real-world genomic testing, treatment, and outcomes in patients with . . .
Three FGFR2 f r patients received an FGFR inhibitor (pemigatinib) as next treatment after testing in 2020 A trend towards longer median overall survival in the f r vs wt group (24 5 vs 17 8 mo), and a correlation of survival with ECOG PS were observed
|
|
|